Join us at JPM26: online & in SF on Jan 12-13
No images? Click here
Breaking down biopharma deals and dollars at JPM
JANUARY 12 - 13, 2026 | 7:00 AM - 5:00 PM PT
MARRIOTT MARQUIS, SAN FRANCISCO | HYBRID
Biopharma's dealmakers, funders and CEOs converge on San Francisco every January for one reason: to figure out where the money goes next. And this year, there's plenty to discuss.
The dealmaking environment has been surprisingly robust despite the sector's ups and downs. M&A closed out 2025 with several acquisitions topping $10 billion, and John Carroll sits down with PwC, Amgen, AbbVie and Merck to break down what that momentum means for the near future. Plus, Centerview Partners' Eric Tokat brings his front-row perspective on the year's biggest transactions and what's driving dealmakers as we head into the new year.
Join us at JPM to find out where the industry stands and where the capital is flowing in 2026.
CHOOSE YOUR PASS
All in-person passes include access to the Endpoints Hub.
Join us in-person on Monday & Tuesday
Join us in-person on Monday or Tuesday
Join us virtually (free)
Joining us with your team? Save 15% when you buy a group pass —You can choose your attendees later.
Includes 3 All-Access passes
AGENDA HIGHLIGHTS
On the IPO front, LB Pharmaceuticals CEO Heather Turner made headlines by taking her company public in September, breaking nearly an eight-month dry spell for US biotech listings. She'll give a behind-the-scenes account of why they went for it and how they pulled it off when most companies were still waiting on the sidelines.
Heather Turner
CEO
LB Pharmaceuticals
We'll also hear from Ivana Magovčević-Liebisch, who navigated Vigil Neuroscience through its Sanofi acquisition and is now leading Draig Therapeutics — she'll walk through how that deal came together and how she's thinking about her next chapter.
NEW: In-person passes include access to our invite-only networking reception, featuring a live taping of Post-Hoc Live and special guest Noubar Afeyan, Founder and CEO of Flagship Pioneering.
Endpoints at JPM26 exclusive data: What biopharma leaders really think about 2026
We're unveiling exclusive data from our new Biopharma Sentiment Index (BPSI), drawn from Endpoints readers who sit at the center of industry decision-making. What do executives actually think when surveyed anonymously about funding trajectories, regulatory challenges, and which therapeutic areas will attract capital?
These conversations will set your agenda for navigating what's ahead. Join us.
Can't make it in-person? Virtual passes are available at no charge.
EVENT SPONSORS
